A brain cancer vaccine arises
In the treatment, surgeons remove the malignant tumor, then isolate and concentrate essential proteins from it and inject them back into the patient’s arm six to eight weeks later. The patient’s immune system recognizes the proteins as invaders and produces billions of T-cells, its natural attack system, to fight it.
The vaccine did so well in Phase I clinical trials for safety that it now has U.S Food and Drug Administration approval to begin Phase II trials for efficacy.
If this phase is successful, Phase III would involve many more patients and could result in final FDA approval in three or four years, Komotar says.
The University of Miami has begun recruiting volunteers for the study.